Effect of adrenergic and cholinergic agents on esophageal bicarbonate secretion in opossums. 1994

B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.

The effects of cholinergic and adrenergic agonists and antagonists on esophageal bicarbonate secretion in the opossum were studied in vivo using a recirculated unbuffered saline solution and pH stat technique. The basal rate of secretion was 0.28 +/- 0.02 mumol.h-1.cm-2, and this increased in a dose-dependent manner by intravenous administration of carbachol (maximal increase 0.74 +/- 0.07 mumol.h-1.cm-2 at 6 micrograms/kg). Furthermore, like carbachol, the acetylcholinesterase inhibitor edrophonium also increased bicarbonate secretion, whereas atropine and pirenzepine, which had no effect on basal secretion, abolished the increase in secretion produced by carbachol. Intravenous administration of either adrenergic agonists or antagonists had no significant effect on secretion. These data indicate that basal bicarbonate secretion in the opossum esophagus is independent of intrinsic adrenergic or cholinergic activity, and so not under autonomic nervous system control, but that endogenous release of acetylcholine, presumably from parasympathetic nervous fibers, can stimulate bicarbonate secretion through activation of cholinergic M1 receptors.

UI MeSH Term Description Entries
D009893 Opossums New World marsupials of the family Didelphidae. Opossums are omnivorous, largely nocturnal and arboreal MAMMALS, grow to about three feet in length, including the scaly prehensile tail, and have an abdominal pouch in which the young are carried at birth. Didelphidae,Opossum
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010277 Parasympathomimetics Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. Parasympathomimetic Agents,Parasympathomimetic Drugs,Parasympathomimetic Effect,Parasympathomimetic Effects,Agents, Parasympathomimetic,Drugs, Parasympathomimetic,Effect, Parasympathomimetic,Effects, Parasympathomimetic
D004947 Esophagus The muscular membranous segment between the PHARYNX and the STOMACH in the UPPER GASTROINTESTINAL TRACT.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001639 Bicarbonates Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity. Bicarbonate,Bicarbonate Ions,Hydrogen Carbonates,Bicarbonate Ion,Carbonic Acid Ions,Hydrogen Carbonate,Carbonate, Hydrogen,Carbonates, Hydrogen,Ion, Bicarbonate,Ions, Bicarbonate,Ions, Carbonic Acid
D013565 Sympatholytics Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. Sympathetic-Blocking Agents,Sympatholytic,Sympatholytic Agent,Sympatholytic Drug,Sympatholytic Agents,Sympatholytic Drugs,Sympatholytic Effect,Sympatholytic Effects,Agent, Sympatholytic,Agents, Sympathetic-Blocking,Agents, Sympatholytic,Drug, Sympatholytic,Drugs, Sympatholytic,Effect, Sympatholytic,Effects, Sympatholytic,Sympathetic Blocking Agents
D013566 Sympathomimetics Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. Amines, Sympathomimetic,Sympathomimetic,Sympathomimetic Agent,Sympathomimetic Drug,Sympathomimetic Agents,Sympathomimetic Drugs,Sympathomimetic Effect,Sympathomimetic Effects,Agent, Sympathomimetic,Agents, Sympathomimetic,Drug, Sympathomimetic,Drugs, Sympathomimetic,Effect, Sympathomimetic,Effects, Sympathomimetic,Sympathomimetic Amines

Related Publications

B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
May 1967, Endocrinology,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
September 1986, The American journal of physiology,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
March 1968, The Indian journal of medical research,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
September 2008, Digestive diseases and sciences,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
January 1982, Scandinavian journal of gastroenterology,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
January 1986, Scandinavian journal of gastroenterology. Supplement,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
January 1988, The Prostate,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
September 1982, Scandinavian journal of gastroenterology,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
January 1997, Acta oto-rhino-laryngologica Belgica,
B H Hamilton, and N A Tobey, and M C Starnes, and V J Schreiner, and R C Orlando
January 1969, Scandinavian journal of gastroenterology,
Copied contents to your clipboard!